In conclusion, our study shows that BRAFAMP and IDH1/2WT is related to the reduced survival in adult patients with glioma compared with BRAFV600E and that BRAFAMP is associated with mutations in IDH1, TP53, and ATRX. This suggests that assessment for BRAFAMP and IDH1/2WT alterations is of prognostic value in adult glioma/glioblastoma patients because patients with this gene alteration pattern have relatively shorter survival times and may benefit from personalized, targeted therapy using BRAF and/or MEK inhibitors. The gene discussed is BRAF; the disease is glioblastoma.